Post the Abbott deal, Piramal Healthcare has been sitting on this pile of cash. There were speculations on insurance, retail, financial services and now they intent to pick up 5.5% stake in Vodafone-Essar.
In an interview to CNBC-TV18, Vikas Dandekar, India bureau chief of Pharmasianews, says the Pirmal-Vodafone deal can be a smart move but the question remains on what happens to the core business. However, he says, over a longer period of time there will be some value accretion. Although Dandekar says Piramal could be eyeing the possible IPO coming up, he further adds, "the IPO doubtful to come out now, considering the present market scene." Below is an edited transcript of Vikas DandekarDiscover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
